Education
About Us
Working with TipRanks
Follow Us
Sana Biotechnology (SANA)
NASDAQ:SANA
SANA Stock Chart & Stats
$4.53
$3.38(204.85%)
At close: 4:00 PM EST
$4.53
$3.38(204.85%)
Day’s Range― - ―
52-Week Range$1.26 - $7.30
Previous CloseN/A
Volume118.31M
Average Volume (3M)5.00M
Market Cap
$1.21B
Enterprise Value$849.74M
Total Cash (Recent Filing)$153.05M
Total Debt (Recent Filing)$89.74M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 24, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding266,366,120
10 Day Avg. Volume5,680,810
30 Day Avg. Volume4,998,539
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.50
Price to Sales (P/S)0.00
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.76
Forecast
1Y Price Target
$7.67Price Target Upside69.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.87
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical SuccessThe 6-month data from the UP421 study demonstrated islet cell survival and function without immunosuppression, signifying a major positive outcome and proof of concept for the HIP platform in treating T1D.
Market OpportunitySana Biotechnology is prioritizing development of SC451 and its in vivo CD8+ T cell CD19 CAR-T, which is seen as a unique niche and significant untapped market opportunity in T1D.
Regulatory ProgressSana recently gained confidence through its FDA INTERACT meeting, providing necessary clarity on its HIP-edited GMP master cell bank and non-clinical testing plan for SC451.
Bears Say
Sana Biotechnology News
SANA FAQ
What was Sana Biotechnology’s price range in the past 12 months?
Sana Biotechnology lowest stock price was $1.26 and its highest was $7.30 in the past 12 months.
What is Sana Biotechnology’s market cap?
Sana Biotechnology’s market cap is $1.21B.
When is Sana Biotechnology’s upcoming earnings report date?
Sana Biotechnology’s upcoming earnings report date is Mar 24, 2026 which is in 87 days.
How were Sana Biotechnology’s earnings last quarter?
Sana Biotechnology released its earnings results on Nov 06, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.189 by $0.029.
Is Sana Biotechnology overvalued?
According to Wall Street analysts Sana Biotechnology’s price is currently Undervalued.
Does Sana Biotechnology pay dividends?
Sana Biotechnology does not currently pay dividends.
What is Sana Biotechnology’s EPS estimate?
Sana Biotechnology’s EPS estimate is -0.14.
How many shares outstanding does Sana Biotechnology have?
Sana Biotechnology has 266,366,120 shares outstanding.
What happened to Sana Biotechnology’s price movement after its last earnings report?
Sana Biotechnology reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.189. Following the earnings report the stock price went up 0.988%.
Which hedge fund is a major shareholder of Sana Biotechnology?
Currently, no hedge funds are holding shares in SANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sana Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.67 (69.32% Upside)
$7.67 (69.32% Upside)
Blogger Sentiment
Bullish
SANA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 733.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
158.85%
12-Months-Change
Fundamentals
Return on Equity
-96.11%
Trailing 12-Months
Asset Growth
-22.16%
Trailing 12-Months
Company Description
Sana Biotechnology
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
SANA Stock 12 Month Forecast
Average Price Target
$7.67
▲(69.32% Upside)
Technical Analysis
Geron
―
Editas Medicine
―
Crispr Therapeutics AG
―
Taysha Gene Therapies
―
Prime Medicine, Inc.
―
Ownership Overview
29.02% Insiders
13.00% Mutual Funds
24.40% Other Institutional Investors
25.67% Public Companies and Individual Investors